Advanced Medical Isotope Corporation Reports Positive Results from Initial Study at WSU
September 26 2017 - 7:22AM
Marketwired
Advanced Medical Isotope Corporation Reports Positive Results
from Initial Study at WSU
RICHLAND, WA-(Marketwired - Sep 26, 2017) - Advanced Medical
Isotope Corporation (OTC PINK: ADMD), a late stage radiation
oncology focused medical device company, is pleased to report
positive results from the initial study of RadioGel™ at Washington
State University (WSU).
In the study, researchers at WSU used RadioGel to treat two cats
for feline sarcoma. The results indicate RadioGel performed as
designed, confirming objective response (destruction of tumor
tissue) without any negative or detrimental side-effects.
"We are thrilled to see confirmation of RadioGel's potential,"
stated Dr. Mike Korenko, CEO of ADMD. "The clinical research team
at WSU safely achieved near-uniform placement of RadioGel under
ultrasound guidance, using the same parallel injection technique
that will also be used to treat human skin cancer tumors."
Subsequent cat subjects referred to WSU will be treated at
higher radiation doses to optimize levels for therapy.
The results of the initial study were published in a report, 'A
Research Update on RadioGel™ for Treating Feline Sarcomas', which
can be viewed on the IsoPet section of ADMD's website
https://www.radiogel.com/isopet/animal-studies-updates. Additional
status and progress updates of future animal testing will also be
made available on this page.
It is estimated six million new cancer diagnoses are made in
dogs and a similar number made in cats each year (see
http://ccr.nci.nih.gov). Treating 0.5% of these cases, at an
estimated price of $5,000, would generate approximately $300
million in annual revenue, significantly higher than the Company's
previous conservative projection of $40 million.
About Advanced Medical Isotope Corporation (OTC PINK: ADMD)
The strategic market sector of ADMD is isotope applications.
Currently, the Company is engaged in the development of RadioGel,
an Yttrium-90 based brachytherapy device, for the treatment of
tumors. Brachytherapy uses radiation to destroy cancerous tumors by
placing a radioactive isotope inside the treatment area.
The company is engaging the FDA for permission to use RadioGel
for the treatment of advanced basal and squamous cell skin cancers.
The IsoPet Solutions division of ADMD is focused on demonstrating
the safety and therapeutic effectiveness for different animal
cancers in four different university veterinary hospitals. ADMD is
positioning itself so that after this demonstration phase, The
Company can begin to generate revenues through the sale of RadioGel
to private animal clinics.
The Company currently is outsourcing material aspects of
manufacturing of its product in the United States and intends to
enter into licensing arrangements outside of the United States for
the manufacturing and distribution of RadioGel in other
countries.
About RadioGel™
RadioGel™ is a hydrogel liquid containing tiny Yttrium-90
phosphate particles to be injected into a tumor. This hydrogel is a
liquid at temperatures below body temperature but begins to gel,
harden, upon injection as the temperature increases to normal body
temperature, thereby locking the particles in place. The particles
emit a very high concentrated and contained beta irradiation to
kill the tumor. The beta radiation has a short penetration distance
so there is minimal collateral damage to healthy tissues outside of
the injected area.
RadioGel™ also has a short half-life - delivering more than 90%
of its therapeutic radiation within 10 days. This compares
favorably to other available treatment options requiring up to 6
weeks or more to deliver a full course of radiation therapy. This
is an outpatient treatment much safer to the personnel treating the
patient than competing brands and the patient can go home
immediately with no risk to family members.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
You can identify these statements by the use of the words "may,"
"will," "should," "plans," "expects," "anticipates," "continue,"
"estimates," "projects," "intends," and similar expressions.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those projected or
anticipated. These risks and uncertainties include, but are not
limited to, the Company's ability to successfully execute its
expanded business strategy, including by entering into definitive
agreements with suppliers, commercial partners and customers;
general economic and business conditions, effects of continued
geopolitical unrest and regional conflicts, competition, changes in
technology and methods of marketing, delays in completing various
engineering and manufacturing programs, changes in customer order
patterns, changes in product mix, continued success in technical
advances and delivering technological innovations, shortages in
components, production delays due to performance quality issues
with outsourced components, regulatory requirements and the ability
to meet them, government agency rules and changes, and various
other factors beyond the Company's control.
We have changed our email and website to reflect our focus on
RadioGel. Please visit our website: www.radiogel.com and a direct
link to recent presentations and interviews at
https://www.redchip.com/company/Biotech/ADMD/376/admd.
Contact Information
CONTACT: Advanced Medical Isotope Corporation Michael K. Korenko
President & CEO MKorenko@RadioGel.com 509-736-4000
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Apr 2023 to Apr 2024